Targets › MMP13
19 programs from 19 companies in 22 trials: 10 Phase 2, 9 Phase 4, 2 Phase 1, 1 Phase 3; Infectious disease, Immunology, Cardiovascular; next expected readout Dec 2026.
Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN. Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CCN2. (UniProt, P45452)
Open in Phaseline: the race on MMP13, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bangrak STIs Center | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Syphilis Infection | May 2027 |
| University of Pennsylvania | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Acne | Jul 2027 |
| Chinese University of Hong Kong | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Sexually Transmitted Diseases, Bacterial | Dec 2027 |
| University of Oxford | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Scrub Typhus | Oct 2028 |
| University of Washington | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Gonorrhea Male; Syphilis | Oct 2028 |
| Emory University | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Sexually Transmitted Infections (STI) | Apr 2029 |
| Westat | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Gonorrhea | Jun 2029 |
| Shanghai Jiao Tong University School of Medicine | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 4 | Helicobacter Pylori Infection | – |
| National University Hospital, Singapore | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 3 | Tuberculosis; Tuberculosis, Meningeal | Nov 2027 |
| Makerere University | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Tuberculosis, Pulmonary | Dec 2026 |
| University of Iowa | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Exudative Macular Degeneration | Dec 2026 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Eczema | Jan 2027 |
| Weill Medical College of Cornell University | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Emphysema | Feb 2027 |
| University of Miami | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Seroma | May 2027 |
| Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit | Doxycycline Hyclate Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Infectious Disease | Dec 2027 |
| Swiss Cancer Institute | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Breast Cancer | Jun 2028 |
| Hawaii Pacific Health | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 2 | Kawasaki Disease | – |
| Massachusetts Eye and Ear Infirmary | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 1 | Neurofibromatosis Type 2 | Dec 2026 |
| University of California, Davis | Doxycycline Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor; Matrix metalloproteinase 13 inhibitor | MMP7, MMP8, MMP13, MMP1 | Phase 1 | Acne Vulgaris | Jan 2027 |
Scrub Typhus (2) Helicobacter Pylori Infection (1) Sexually Transmitted Infections (STI) (1) Tuberculosis (1) Tuberculosis, Meningeal (1) Gonorrhea Male (1) Syphilis (1) Sexually Transmitted Diseases, Bacterial (1) Neurofibromatosis Type 2 (1) Breast Cancer (1) Seroma (1) Eczema (1)
small molecule (19)
Shanghai Jiao Tong University School of Medicine (1) Emory University (1) National University Hospital, Singapore (1) University of Washington (1) University of Oxford (1) Chinese University of Hong Kong (1) Massachusetts Eye and Ear Infirmary (1) Swiss Cancer Institute (1) University of Miami (1) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) Weill Medical College of Cornell University (1) University of Iowa (1) University of California, Davis (1) Makerere University (1) Westat (1) Bangrak STIs Center (1) Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (1) University of Pennsylvania (1) Hawaii Pacific Health (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.